Zobrazeno 81 - 90
of 133
pro vyhledávání: ''
Autor:
Melanie San Pedro-Salcedo, A. Dimitrios Colevas, Heather A. Wakelee, Jonathan W. Riess, Kristen N. Ganjoo, Calvin J. Kuo, Yelena Krupitskaya, Christelle Clément-Duchêne, Aaron C Logan, Sukhmani K. Padda
Publikováno v:
Cancer investigation. 30(3)
We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin c
Autor:
Nobuya Karimine, Shigeru Nanbara, Tsuyoshi Akiyoshi, Kiyoshi Takamuku, Hiroaki Ueo, Daisuke Watanabe, Tsukasa Asoh, Ryoji Abe, Shinya Arinaga, Hiroshi Inoue
Publikováno v:
Cancer Investigation. 12:588-596
Based on our clinical findings that the ability of cancer patients to generate lymphokine-activated killer (LAK) cells was remarkably augmented after mitomycin C (MMC) administration, we designed a treatment regimen that consisted of MMC 12 mg/m2, i.
Autor:
Justin F. Doan, Deepa Lalla, Robert J. Herbert, Robert I. Griffiths, Melissa Brammer, Mark D. Danese
Publikováno v:
Cancer Investigation
We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Ove
Autor:
Philippe Chollet, Catherine Abrial, C. Pomel, Emilie Thivat, Marie-Ange Mouret-Reynier, Jean-Marc Nabholtz, Fabrice Kwiatkowski, Jean-Pierre Ferriere, Eloise Planchat, Xavier Durando
Publikováno v:
Cancer investigation. 29(9)
Classical prognostic factors of breast cancer are correlated to disease-free survival and overall survival (OS); their precise role is less known on metastatic disease. A total of 511 breast cancer patients without initial metastasis were treated. OS
Autor:
Ming Zhao, Ni Yin, Bangliang Yin, Fenglei Yu, Jianguo Hu, Chen Chen, Bin He, Qianjin Lu, Baoxiang Wang, Yunchang Yuan
Publikováno v:
Cancer investigation. 29(8)
To investigate whether alterations in histone modifications occur in esophageal squamous cell carcinoma (ESCC), we measured histone H3/ H4 acetylation and H3K4/H3K27 methylation levels, as well as the expression of chromatin modifier genes in tumor a
Publikováno v:
Cancer investigation. 29(4)
Somatic mutations of phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) play an important role in tumorigenesis. Using PCR-SSCP, followed by sequencing, we examined the PIK3CA gene over the previously identified mutational hotspots in a
Publikováno v:
Cancer Investigation. 11:247-251
This phase I study of 36 patients was performed to identify the maximal tolerated dose of oral calcium leucovorin (CLV) that could be concomitantly administered with protracted 5-fluorouracil (5-FU) infusion (greater than 30 days). Administration of
Autor:
John P. Chute, Ashley Morris, Christopher A Crout, Zhiguo Li, Bercedis Peterson, Robert W. Storms, Mitchell E. Horwitz, Anand S. Lagoo, Jared Golob, Anne W. Beaven, Cristina Gasparetto, Yiping Yang, Keith M. Sullivan, Nelson J. Chao, David A. Rizzieri, Gwynn D. Long
Publikováno v:
Cancer investigation. 29(1)
High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the feasibili
Autor:
Toshio Yawata, Kae Chang Park, Eiichi Nakai, Ayano Kumazawa, Keiji Shimizu, Takahiro Chihara, Hiromichi Nakabayashi
Publikováno v:
Cancer investigation. 27(9)
We established a cancer stem (CS) cell line, U87CS, by means of spheroid culture of U87MG cells derived from glioblastoma (GBM) in neuronal stem cell medium. U87CS cells presented positive immunohistochemical staining for multidrug resistance (MDR)1
Autor:
Ivan Bièche, Ingrid Laurendeau, Delia Garrido, Nicky D'Haene, Armando Basso, Marcela Maria Ferrer, Patricia Ciavarelli, Isabelle Salmon, Michel Vidaud, Irene Szijan
Publikováno v:
Cancer investigation. 27(6)
ErbB family receptors mediate major cellular functions implied in tumorigenesis, though their role in meningiomas was not thoroughly studied. Meningiomas represent 30% of primary cranial tumors, are mostly benign, and prevail in the second half of li